Secondly, it is important to acknowledge that administration of mineralocorticoid receptor agonists (MRAs) and sodium–glucose cotransporter 2 (SGLT2) inhibitors lowers the risk of atrial arrhythmia recurrence following AF ablation [31,32]. Here, SLC5A2 is linked to atrial fibrillation.